A 28-year-old Indian woman presents with progressive darkening of urine over 2 years, joint pain in the spine and large joints, and bluish-black pigmentation of the sclera and cartilage. Urine turns black upon standing or alkalization. Serum creatinine is elevated. Which enzyme deficiency explains these findings?

## Clinical Diagnosis: Alkaptonuria This patient presents with the classic tetrad of **alkaptonuria** (tyrosinemia type III), caused by homogentisate oxidase deficiency. ### Biochemical Defect **Key Point:** Homogentisate oxidase catalyzes the oxidative cleavage of the benzene ring in homogentisate, converting it to maleylacetoacetate in the tyrosine degradation pathway. When this enzyme is deficient: - Homogentisate accumulates in blood and is excreted in urine - Upon exposure to air or alkaline pH, homogentisate undergoes oxidation and polymerization - This produces a dark brown/black pigment (alkapton) - The pigment deposits in connective tissues (ochronosis) and urine darkens ### Metabolic Pathway Block ```mermaid flowchart TD A[Tyrosine] --> B[DOPA] B --> C[Homogentisic acid] C -->|Homogentisate oxidase| D[Maleylacetoacetate] D --> E[Fumarylacetoacetate] E --> F[Acetoacetyl-CoA + Fumarate] C -->|Deficiency| G[Accumulation & Excretion]:::urgent G --> H[Dark urine on standing]:::outcome G --> I[Ochronosis pigment deposition]:::outcome ``` ### Clinical Features of Alkaptonuria | Feature | Timing | Mechanism | |---------|--------|----------| | Dark urine | Infancy/early childhood | Homogentisate oxidation in urine | | Ochronosis | 2nd–3rd decade | Pigment deposition in cartilage, sclera, skin | | Arthropathy | 3rd–4th decade | Pigment deposition in intervertebral discs and joints; degenerative changes | | Kidney stones | Variable | Homogentisate crystallization | | Cardiac valve disease | Late | Pigment deposition on valves | ### Why Urine Turns Black **Clinical Pearl:** The urine darkening is pathognomonic: - Fresh urine is colorless or pale - Upon standing (exposure to air/O₂) or addition of alkali, homogentisate oxidizes - The resulting melanin-like polymer is dark brown/black - This is a diagnostic clue that should prompt testing ### Inheritance and Epidemiology **High-Yield:** Alkaptonuria is inherited in an **autosomal recessive** pattern. It is one of the first genetic diseases described by Garrod (1902). Incidence is ~1 in 250,000 to 1 in 1,000,000 globally, but higher in consanguineous populations. ### Diagnosis - **Urine homogentisic acid:** Elevated (diagnostic) - **Plasma homogentisate:** Mildly elevated - **Genetic testing:** Mutations in HGD gene confirm diagnosis - **Imaging:** Ochronosis visible on sclera, cartilage; degenerative disc disease on spine imaging ### Management **Key Point:** No enzyme replacement available. Management is supportive: - High-dose vitamin C (reduces homogentisate oxidation) - Nitisinone (inhibits 4-hydroxyphenylpyruvate dioxygenase upstream, reducing homogentisate production) — emerging therapy - NSAIDs for arthropathy - Monitoring for renal and cardiac complications ### Mnemonic: ALKAPT **Alkapt:** Alkaptonuria = Accumulation of homogentisate, Liver disease (rare), Kidney stones, Arthritis (late), Pigmentation (ochronosis), Tyrosine metabolism block [cite:Harper's Biochemistry 31e Ch 27; Robbins 10e Ch 5]